These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 17702698)
1. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698 [TBL] [Abstract][Full Text] [Related]
2. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592 [TBL] [Abstract][Full Text] [Related]
3. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945 [TBL] [Abstract][Full Text] [Related]
4. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Qiang YW; Chen Y; Stephens O; Brown N; Chen B; Epstein J; Barlogie B; Shaughnessy JD Blood; 2008 Jul; 112(1):196-207. PubMed ID: 18305214 [TBL] [Abstract][Full Text] [Related]
5. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Qiang YW; Chen Y; Brown N; Hu B; Epstein J; Barlogie B; Shaughnessy JD Br J Haematol; 2010 Mar; 148(5):726-38. PubMed ID: 19961481 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. van der Horst G; van der Werf SM; Farih-Sips H; van Bezooijen RL; Löwik CW; Karperien M J Bone Miner Res; 2005 Oct; 20(10):1867-77. PubMed ID: 16160745 [TBL] [Abstract][Full Text] [Related]
7. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. Døsen G; Tenstad E; Nygren MK; Stubberud H; Funderud S; Rian E BMC Immunol; 2006 Jun; 7():13. PubMed ID: 16808837 [TBL] [Abstract][Full Text] [Related]
8. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Fowler JA; Mundy GR; Lwin ST; Edwards CM Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979 [TBL] [Abstract][Full Text] [Related]
9. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576 [TBL] [Abstract][Full Text] [Related]
10. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma. Dun X; Jiang H; Zou J; Shi J; Zhou L; Zhu R; Hou J Mol Cancer; 2010 Sep; 9():247. PubMed ID: 20846389 [TBL] [Abstract][Full Text] [Related]
12. Wnt and BMP signaling pathways co-operatively induce the differentiation of multiple myeloma mesenchymal stem cells into osteoblasts by upregulating EMX2. Wei XF; Chen QL; Fu Y; Zhang QK J Cell Biochem; 2019 Apr; 120(4):6515-6527. PubMed ID: 30450775 [TBL] [Abstract][Full Text] [Related]
17. Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells. Faraahi Z; Baud'huin M; Croucher PI; Eaton C; Lawson MA Bone; 2019 May; 122():82-92. PubMed ID: 30776499 [TBL] [Abstract][Full Text] [Related]
18. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428 [TBL] [Abstract][Full Text] [Related]
20. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model. Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]